Drug Trial Radar · NCT02978183
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
Last checked: Nov 19, 2026Latest source record: Apr 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Dec 2016
Primary completion
Feb 2017
Study completion Nov 2017
Sponsor
- Lead sponsor
- Noveome Biotherapeutics, formerly StemnionIndustry
- Sponsor type
- Industry
- First posted
- Nov 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
Conditions
- Allergic Conjunctivitis
Interventions
ST266Biological
One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
Saline (0.9% NaCl)Drug
One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular ItchingTime frame: Day 7 and 8
- Conjunctival RednessTime frame: Day 7 and 8
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Andover, Massachusetts
Site not named
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.